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 The pathogenesis of heart failure with a
preserved ejection fraction (HFpEF) is
unclear.
 Cardiosphere-derived cells (CDCs) are
heart-derived cell products with anti-
ﬁbrotic and anti-inﬂammatory properties,
which have been implicated in HFpEF.
 Dahl salt-sensitive rats were fed a high-
salt diet for 6 to7 weeks and randomized
to receive intracoronary CDCs or placebo.
 Following CDC treatment, diastolic
dysfunction resolved in treated rats but
not in the placebo group. Treatment
with CDCs also lower LV end-diastolic
pressure, decrease lung congestion, and
enhance survival.
 CDC treatment decreased LV ﬁbrosis and
inﬂammatory inﬁltrates, and reversed
many of the transcriptomic changes
associated with HFpEF, but had no effect
on cardiac hypertrophy.
 By selectively reversing inﬂammation and
ﬁbrosis, CDCs may be beneﬁcial in the
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15SUMMARYThe pathogenesis of heart failure with a preserved ejection fraction (HFpEF) is unclear. Myocardial ﬁbrosis,
inﬂammation, and cardiac hypertrophy have been suggested to contribute to the pathogenesis of HFpEF.
Cardiosphere-derived cells (CDCs) are heart-derived cell products with antiﬁbrotic and anti-inﬂammatory
properties. This study tested whether rat CDCs were sufﬁcient to decrease manifestations of HFpEF in hy-
pertensive rats. Starting at 7 weeks of age, Dahl salt-sensitive rats were fed a high-salt diet for 6 to 7 weeks
and randomized to receive intracoronary CDCs or placebo. Dahl rats fed normal chow served as controls.
High-salt rats developed hypertension, left ventricular (LV) hypertrophy, and diastolic dysfunction, without
impairment of ejection fraction. Four weeks after treatment, diastolic dysfunction resolved in CDC-treated
rats but not in placebo. The improved LV relaxation was associated with lower LV end-diastolic pressure,
decreased lung congestion, and enhanced survival in CDC-treated rats. Histology and echocardiography
revealed no decrease in cardiac hypertrophy after CDC treatment, consistent with the ﬁnding of sustained,
equally-elevated blood pressure in CDC- and placebo-treated rats. Nevertheless, CDC treatment decreased
LV ﬁbrosis and inﬂammatory inﬁltrates. Serum inﬂammatory cytokines were likewise decreased after CDC
treatment. Whole-transcriptome analysis revealed that CDCs reversed changes in numerous transcripts
associated with HFpEF, including many involved in inﬂammation and/or ﬁbrosis. These studies suggest that
CDCs normalized LV relaxation and LV diastolic pressure while improving survival in a rat model of HFpEF.
The beneﬁts of CDCs occurred despite persistent hypertension and cardiac hypertrophy. By selectively
reversing inﬂammation and ﬁbrosis, CDCs may be beneﬁcial in the treatment of HFpEF. (J Am Coll Cardiol
Basic Trans Sci 2016;1:14–28) © 2016 The Authors. Published by Elsevier on behalf of the American College of
Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).SEE PAGE 29
AB BR E V I A T I O N S
AND ACRONYM S
CDC = cardiosphere-derived
cell
DS = Dahl salt-sensitive
E/A ratio = ratio of early to
late ventricular ﬁlling velocity
HFpEF = heart failure with
preserved ejection fraction
LV = left ventricular
LVEDP = left ventricular
end-diastolic pressure
LVEF = left ventricular
ejection fraction
MMP = matrix
metalloproteinase
TIMP = tissue inhibitor ofH eart failure with preserved ejection fraction(HFpEF) has become a major public healthconcern. Its increasing prevalence now ex-
ceeds that of heart failure with reduced ejection frac-
tion (1–3). Outcomes of patients with HFpEF are poor
(4,5), and so far, no treatment has been shown
to decrease morbidity or mortality (3,6). HFpEF is
associated with various cardiovascular risk factors
(especially hypertension), extracardiac comorbid-
ities, and aging. The net result is impaired diastolic
relaxation and ﬁlling of the left ventricle, increased
myocardial stiffness, impaired vascular compliance,
and increased diastolic pressure (7,8). Myocardial
ﬁbrosis and inﬂammation have been associated with
HFpEF (9–14) and with the transition from hyperten-
sive left ventricular (LV) hypertrophy without HFpEF
to hypertensive LV hypertrophy with HFpEF (15).
Cardiosphere-derived cells (CDCs) are heart cell prod-
ucts with antiﬁbrotic, anti-inﬂammatory, and angio-
genic properties (16–20). CDCs, which are currently
in phase 2 human trials for scar reduction after
myocardial infarction (5), have been shown to be
beneﬁcial in models of ischemic (17,18,21) and noni-
schemic cardiomyopathy (16). Thus, we wondered
whether CDCs might have disease-modifying activity
in HFpEF.Dahl salt-sensitive (DS) rats develop hypertension,
hypertrophy, and, eventually, HFpEF on a high-salt
diet (22–26). Increased ﬁbrosis and inﬂammationunderlie the development of HFpEF, with resultant
cachexia, pulmonary congestion, and accelerated
mortality (22,26,27). Therefore, this model has
been widely used to test new treatments for
HFpEF (23,27–31). Here, we tested the efﬁcacy
of CDCs in improving LV structure and func-
tion and overall outcome in DS rats with
HFpEF.
METHODS
An expanded “Methods” section is available
in the Supplemental Appendix.
DS rats (Charles River, Wilmington, Mas-
sachusetts) were fed a 0.3% NaCl (low-salt)
diet until 7 weeks of age. At that time, the
diet was switched to an 8% NaCl (high-salt)
diet in 54 rats by random assignment. DS rats
fed the low-salt diet constituted the control
group (n ¼ 18). At 13 to 14 weeks of age, rats
on the high-salt diet were randomized tometalloproteinase
FIGURE 1 Rat Model of HFpEF: Phenotype and Responsiveness to Treatment With Cardiosphere-Derived Cells
(A) Study design. (B) Cardiosphere-derived cell manufacturing protocol. (C) Representative images of transmitral ﬂow by Doppler echocardiography at endpoint in
control, placebo-treated, and cardiosphere-derived cell (CDC)–treated rats. (D) CDC treatment normalizes ratio of early to late ventricular ﬁlling velocity (E/A ratio) at 4
weeks, while the E/A ratio in placebo-treated rats remains depressed. Systolic function assessed by left ventricular ejection fraction (LVEF) (E,F) and by fractional area
change (FAC) (G,H) is equivalent in all groups. Left ventricular end-diastolic and end-systolic volumes (I) are equivalent in all groups. (J) CDC treatment halts heart
failure with preserved ejection fraction–related left atrial enlargement, while placebo does not. (Baseline and pre-treatment, n ¼ 10 for control rats and n ¼ 24 for
placebo- and CDC-treated rats; 1 week post-treatment, n ¼ 10 for control rats, n ¼ 21 for placebo- and CDC-treated rats; at endpoint, n ¼ 10 for control rats, n ¼ 15 for
placebo-treated rats, n ¼ 18 for CDC-treated rats). *p< 0.05 versus placebo and CDC groups and †p< 0.05 versus placebo, both by analysis of variance. LAV¼ left atrial
volume; LVV ¼ left ventricular volume; PBS ¼ phosphate-buffered saline; ttt ¼ treatment.
Gallet et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 1 - 2 , 2 0 1 6
Cell Therapy With CDCs in HFpEF J A N U A R Y / F E B R U A R Y 2 0 1 6 : 1 4 – 2 8
16receive allogeneic rat CDCs (5  105 resuspended in
100 ml phosphate-buffered saline) (Figure 1A) or
vehicle (phosphate-buffered saline). CDCs were
grown from a freshly explanted Wistar-Kyoto rat
heart as previously described (19) (Figure 1B).
Echocardiography was performed at baseline,
before treatment, and 1 and 4 weeks after treatment
to assess systolic and diastolic function. Invasive
hemodynamic measurements were performed at
endpoint to record systemic pressure and LV pres-
sures and volumes. Pressure-volume loops were
generated from these recordings. Rats were then
euthanized and hearts were harvested for analysis.
Additional follow-up (7 rats in each group,
randomly chosen from the rats alive at 4 weeks)was performed for extended survival analysis (up to
6 weeks) to investigate the longer term effects of
treatment.
STATISTICAL ANALYSIS. Continuous variables are
presented asmeanSD in the text andmeanSE in the
ﬁgures. Categorical variables are expressed as absolute
numbers and percentages. Normal distribution of
variables was assessed using the Kolmogorov-Smirnov
test. If normality was established, independent groups
(n ¼ 2) were compared using unpaired Student t test,
and multiple groups were compared using 1-way
analysis of variance. For variables not normally
distributed, the Mann-Whitney U test was used for
comparisons of 2 groups, and the Kruskal-Wallis test
TABLE 1 Characteristics of Rats Fed High- and Low-Salt Diets Before (Baseline) and
After 6 Weeks of Diet
Baseline 6 Weeks
Low Salt High Salt p Value Low Salt High Salt p Value
SBP (mm Hg) NA NA 133  23 188  17* 0.001
DBP (mm Hg) NA NA 92  15 130  12* 0.001
LVEF (%) 73.1  4.8 73.0  5.1 0.90 71.6  3.8 74.4  5.9 0.10
FAC (short axis) (%) 64.1  3.0 64.2  4.9 0.95 62.3  4.6 63.2  5.9 0.61
AW thickness (mm) 1.2  0.1 1.2  0.1 0.54 1.2  0.1 1.8  0.2* <0.001
PW thickness (mm) 1.3  0.1 1.3  0.1 0.27 1.3  0.1 2.0  0.3* <0.001
LVEDV (ml) 330  46 329  70 0.93 484  112 510  110 0.42
LVESV (ml) 89  22 89  28 0.98 142  47 130  50 0.37
E/A ratio 1.7  0.2 1.7  0.3 0.66 1.7  0.2 1.2  0.2* <0.001
Left atrial area (mm2) 13.7  1.9 14.1  1.9 0.55 17.9  1.7 21.2  2.9* <0.001
Heart weight (g) NA NA 1.42  0.14 1.67  0.10* 0.03
Heart weight/body
weight (mg/g)
NA NA 4.1  0.4 5.2  0.5* 0.016
Values are mean  SD. *p < 0.05 between high-salt and low-salt groups at 6 weeks.
AW ¼ anterior wall; DBP ¼ diastolic blood pressure; E/A ratio ¼ ratio of early to late ventricular ﬁlling velocity;
FAC ¼ fractional area change; LVEDV ¼ left ventricular end-diastolic volume; LVEF ¼ left ventricular ejection
fraction; LVESV ¼ left ventricular end-systolic volume; NA ¼ not available; PW ¼ posterior wall; SBP ¼ systolic
blood pressure.
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17was used to compare multiple groups. Bonferroni
correction was applied to every pairwise comparison
performed after analysis of variance or the
Kruskal-Wallis test. Survival analysis was performed
using Kaplan-Meier analysis. A p value <0.05 was
considered to indicate statistical signiﬁcance.
RESULTS
BLOOD PRESSURE AND CARDIAC HYPERTROPHY.
Table 1 shows characteristics of the high-salt and
control animals at baseline and after 6 weeks of diet
(13 weeks of age). As expected (25), rats fed a
high-salt diet developed hypertension and cardiac
hypertrophy after 6 weeks, but low-salt control rats
did not. Those changes were associated with dia-
stolic dysfunction, as shown by a decreased ratio of
early (E) to late (A) ventricular ﬁlling velocity (E/A
ratio) by echocardiography (1.7  0.2 vs. 1.2  0.2,
p < 0.001), without any changes in LV volumes, LV
ejection fraction (LVEF) or fractional area change
(Table 1).
ECHOCARDIOGRAPHIC STUDIES: CDCs NORMALIZE
E/A RATIO. Having conﬁrmed the presence of
cardiac hypertrophy and diastolic dysfunction, we
randomly allocated rats to intracoronary CDC or
vehicle infusion. Figure 1C shows representative
images of transmitral ﬂow at endpoint in control,
placebo-treated, and CDC-treated animals. Pooled
data (Figure 1D) revealed that after 6 weeks of diet but
before treatment, E/A ratios were similar in the pla-
cebo and CDC groups but lower than in control rats.
Likewise, left atrial size was higher in the
high-salt-fed rats compared with control rats, indi-
cating already increased LV ﬁlling pressure. After
intracoronary infusion of CDCs (but not placebo), E/A
ratio increased over time (Figure 1D), a change that
was evident as soon as 1 week after treatment. At
endpoint, E/A ratios had returned to control levels
in CDC-treated animals (1.7  0.2 for CDC-treated
vs. 1.8  0.16 for control rats, p ¼ 0.36), whereas
they remained depressed in placebo-treated animals
(1.2  0.3, p < 0.001 vs. CDC-treated rats and vs.
control rats), indicating a likely normalization of LV
relaxation with CDC treatment (an interpretation
veriﬁed later by hemodynamic recordings). In addi-
tion, left atrial dimensions kept increasing in the
placebo animals, while CDC treatment halted left
atrial enlargement. In contrast, LVEF (measured in
long-axis views) (Figures 1E and 1F), fractional area
change (from short-axis views) (Figures 1G and 1H),
and LV volumes (Figures 1I and 1J) were equivalent in
all groups.HEMODYNAMIC STUDIES: CDC TREATMENT NORMALIZES
LV RELAXATION AND PREVENTS ELEVATION OF LV
END-DIASTOLIC PRESSURE. Figure 2A shows represen-
tative recordings of pressure-volume loop families
at endpoint. The time constant of isovolumic LV
pressure fall (tau) was prolonged in placebo-treated
animals compared with CDC-treated animals (21 
8 s vs. 13  1 s in control rats [p ¼ 0.011] and 14 
4 s in CDC-treated rats [p ¼ 0.006]) (Figure 2B) and
control rats, while dP/dt minimum was lower,
indicating impaired relaxation (Figure 2C) without
changes in dP/dt maximum (Figure 2D). In parallel,
pressure-volume loop analyses conﬁrmed that LV
distensibility was decreased in the placebo-treated
animals, as demonstrated by the steeper slope of
the end-diastolic pressure-volume relationship in
placebo-treated animals compared with CDC-treated
and control animals (Figure 2E), again without
changes in the end-systolic pressure-volume rela-
tionship (Figure 2F). LVEDP was 2-fold higher
in placebo-treated than in CDC-treated and control
animals (17  10 mm Hg vs. 9  4 mm Hg in
control rats [p ¼ 0.015] and 8  3 mm Hg in
CDC-treated rats [p ¼ 0.002]) (Figure 2G). The
normalization of LVEDP and tau in CDC-treated
rats conﬁrms that the increase of E/A ratio over
time in this group was due to normalization of LV
relaxation rather than to progression toward a
pseudonormal pattern of transmitral ﬂow (which
FIGURE 2 Hemodynamic Analysis of Control (Low Salt), High Salt Placebo (HFpEF Phenotype), and High-Salt CDC-Treated Rats
(A) Representative pressure-volume (PV) loop recordings in control, placebo-treated, and cardiosphere-derived cell (CDC)–treated rats. CDCs
normalize tau (B) and dP/dt minimum (C) in rats with heart failure with preserved ejection fraction without change in dP/dt maximum (D). PV
loop analysis reveals normalization of the slope of the end-diastolic PV relationship (EDPVR) (E), with no change in the end-systolic PV
relationship (ESPVR) (F). Left ventricular end-diastolic pressure (LVEDP) is normal in the CDC-treated but not the placebo-treated animals (G).
The differences between CDC- and placebo-treated rats are not related to changes in systolic blood pressure (SBP) (H) or diastolic blood
pressure (DBP) (I) or heart rate (HR) (J) (n ¼ 8 for control rats and n ¼ 12 for placebo- and CDC-treated rats; for PV loop families, n ¼ 6 for
control rats, n ¼ 7 for placebo-treated rats, and n ¼ 8 for CDC-treated rats). *p < 0.05 versus placebo- and CDC-treated rats, †p < 0.05 versus
control and CDC-treated rats, and ‡p < 0.05, all by analysis of variance.
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18would have been associated with increased LVEDP
and tau [32]).
We did not observe any differences in blood pres-
sure or heart rate between CDC- and placebo-treated
animals that could have confounded relaxation and
LVEDP measurements (although blood pressure was
lower in the control group, as expected) (Figures 2H
to 2J). Thus, the improvements in diastolic functionwere not due to antihypertensive or chronotropic
effects of CDCs.
CDC TREATMENT IMPROVES SURVIVAL AND DECREASES
LUNG CONGESTION. Consistent with the improvement
of diastolic function, we observed a dramatic
improvement of survival in CDC-treated rats
(Kaplan-Meier survival curves) (Figure 3A) (log-rank
FIGURE 3 Effects of CDCs on Mortality and Heart Failure
Cardiosphere-derived cell (CDC) treatment improves survival (A; X axis shows days from
treatment, or equivalent age in control rats) and pulmonary congestion (B) (lung weight
[left] and lung weight/body weight [right]) in rats with heart failure with preserved
ejection fraction (HFpEF). (C) At endpoint, body weight loss induced by HFpEF is partially
restored by CDC treatment (n ¼ 10 for control rats, n ¼ 15 for placebo-treated rats, and
n ¼ 18 for CDC-treated rats). Log-rank for CDCs versus placebo. *p < 0.05 versus placebo-
and CDC-treated rats, †p < 0.05 versus control and CDC-treated rats, and ‡p < 0.05
versus placebo-treated rats, all by analysis of variance. ttt ¼ treatment.
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 1 - 2 , 2 0 1 6 Gallet et al.
J A N U A R Y / F E B R U A R Y 2 0 1 6 : 1 4 – 2 8 Cell Therapy With CDCs in HFpEF
19p ¼ 0.027). Post-mortem lung weight and lung
weight/body weight ratios were higher in
placebo-treated rats, indicative of pulmonary
congestion (Figure 3B). In parallel, Figure 3C shows
that animals treated with CDCs resumed some
physiological weight gain, while placebo rats lost
weight, presumably because of cardiac cachexia
(an impression that was conﬁrmed visually).
MECHANISM. Improvement of LV relaxation is not
associated with quantitative changes in cardiac
hypertrophy. LV hypertrophy (both macroscopic and
cellular) can occur with or without diastolic
dysfunction. We quantiﬁed cardiac hypertrophy us-
ing LV wall thickness by echocardiography, heart
weight, and cardiomyocyte cross-sectional area.
Notably, the CDC-related improvement in diastolic
function was not due to a decrease in cardiac hyper-
trophy: wall thickness by echocardiography
(Figure 4A), as well as post-mortem heart weight and
cardiomyocyte cross-sectional area (Figure 4B),
remained equivalent in the CDC and placebo groups.
Thus, CDCs were salutary without decreasing cardiac
hypertrophy.
Antiﬁbrotic effect of CDCs. Fibrosis is increased in
HFpEF (10,12,33). We assessed ﬁbrosis using
picrosirius red staining for total collagen and
semiquantitative reverse transcriptase polymerase
chain reaction to measure transcript levels for
collagen 1 and 3. Figure 5A shows representative
images of hearts stained with picrosirius red.
Overall LV and right ventricular ﬁbrosis was 2-fold
higher in placebo- versus CDC-treated rats; ﬁbrosis
in the latter approached control values (Figures 5B
and 5C). Concomitantly, collagen 1 and collagen 3
in the left ventricle (quantiﬁed by western blot)
were higher in placebo-treated rats than in control
or CDC-treated rats (Figure 5D). Moreover, cardiac
myoﬁbroblasts increased dramatically in placebo-
treated, but not in CDC-treated, DS rats
(Figure 5E). Also, transcript levels of matrix metal-
loproteinase (MMP)-2, MMP-7, MMP-9, and tissue
inhibitor of metalloproteinase (TIMP)-1 as well as
collagen 1A1 and collagen 3 were higher in the
placebo-treated animals compared with the control
and CDC-treated animals (which had similar levels)
(Supplemental Figure 1). These increased transcript
levels are suggestive of increased extracellular
matrix turnover associated with HFpEF, which is
normalized by CDC treatment. Because we did not
measure the extent of ﬁbrosis before treatment, we
cannot distinguish between CDC-induced preven-
tion of new ﬁbrosis and regression of establishedﬁbrosis in the present study. However, previous
work in chronic myocardial infarction models
(20,21,34) and in humans (35,36) has shown that
CDCs (and cardiospheres) can reduce established
scar.
Attenuation of inﬂammation. HFpEF is associated with
increased levels of circulating cytokines and inﬁl-
tration of macrophages and other inﬂammatory
cells in the heart (9). Quantiﬁcation of cytokines in
the serum revealed lower levels of proinﬂammatory
and proﬁbrotic cytokines in CDC-treated rats
compared with placebo-treated rats; the levels in
CDC-treated rats were comparable with those in
FIGURE 4 Beneﬁt of Cardiosphere-Derived Cell Treatment Is Not Related to Decreased Cardiac Hypertrophy
Cardiac anterior wall (AW) and posterior wall (PW) thickness by echocardiography (A), heart weight and heart weight/body weight ratio (B),
and cross-sectional cardiomyocyte area (CSA) (C) are equally elevated in placebo- and cardiosphere-derived cell (CDC)–treated rats relative
to control. n ¼ 10 for control rats, n ¼ 15 for placebo-treated rats, and n ¼ 18 for CDC-treated rats in A; n ¼ 6, n ¼ 11, and n ¼ 14, respectively,
in B; n ¼ 5 in each group in C. *p < 0.05 versus placebo- and CDC-treated rats by analysis of variance.
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20control rats (Figure 6A). Among those cytokines,
some have been linked to the development of HFpEF
(especially monocyte chemotactic protein-1, inter-
leukin-6, and tumor necrosis factor-a) and to the
accumulation of collagen (TIMP-1) (12,37). CDC treat-
ment was also associated with a 2-fold reduction ofmacrophages (CD68-positive cells) and leukocytes
(CD45-positive cells) in the heart compared with
placebo, approaching control levels (Figure 6B).
Vesse l dens i ty and cel l p ro l i ferat ion . Because
microvascular rarefaction has been associated with
HFpEF in numerous studies (38–40), we investigated
FIGURE 5 Antiﬁbrotic Effects Underlie the Beneﬁts of CDCs in HFpEF
(A) Representative heart sections stained with picrosirius red in control, placebo-treated, and cardiosphere-derived cell (CDC)–treated rats. Left
ventricular (LV) ﬁbrosis (B) and right ventricular (RV) ﬁbrosis (C) quantiﬁed from such images is higher in placebo- than in CDC-treated
and control rats. (D) Collagen 1A1 and collagen 3 content is higher in placebo- than in CDC-treated and control rats. (E) Immunostaining for
a–smooth muscle actin (SMA) in control and placebo- and CDC-treated rats. Myoﬁbroblast inﬁltration into the heart is higher in placebo- than
in CDC-treated and control rats. n ¼ 6 to 8 in each group. †p < 0.05 versus control and CDC-treated rats by analysis of variance.
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21arteriolar and capillary density in the left ventricle
(Figure 7A). Both vascular densities were lower in
placebo-treated rats compared with control rats
(Figures 7B and 7C); CDC treatment normalizedarteriolar density and signiﬁcantly increased capillary
density compared with placebo, although capillary
density did not reach the value measured in control
rats. Parallel measurements of cell proliferation using
FIGURE 6 Anti-Inﬂammatory Effects of CDCs in HFpEF
(A) Cardiosphere-derived cell (CDC) treatment normalizes the expression of proinﬂammatory and proﬁbrotic cytokines in serum, including
tumor necrosis factor (TNF)-a, interleukin (IL)-6, monocyte chemotactic protein (MCP)-1, and tissue inhibitor of metalloproteinase (TIMP)-1
(n ¼ 4 in each group). (B) CDC treatment decreases myocardial inﬁltration by macrophages (CD68) and leukocytes (CD45) in the left ventricle
(n ¼ 5 in each group). *p < 0.05 versus placebo- and CDC-treated rats and †p < 0.05 versus control and CDC-treated rats, by nonparametric
tests for (A) and by analysis of variance for (B). CINC ¼ cytokine-induced neutrophil chemoattractant; CINC ¼ cytokine-induced neutrophil
chemoattractant; CNTF ¼ ciliary neurotrophic factor; GMCSF ¼ granulocyte-macrophage colony-stimulating factor; INF ¼ interferon;
IL ¼ interleukin; NGF ¼ nerve growth factor; VEGF ¼ vascular endothelial growth factor.
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22Ki67 immunostaining (Figure 7D) revealed that CDCs
stimulated cardiomyocyte proliferation (cells positive
for both a-sarcomeric actinin and Ki67) (Figure 7E).
In contrast, the number of proliferating ﬁbroblasts
(Ki67-positive, vimentin-positive cells) was greatlyincreased in placebo-treated (but not CDC-treated)
high-salt DS rat hearts relative to low-salt control
rats (Figure 7F).
Next-generat ion r ibonuc le ic ac id sequenc ing .
Next-generation sequencing was performed in the
FIGURE 7 Microvascular Density and Cardioproliferation Enhanced by CDCs, While Fibroblast Proliferation Is Suppressed
(A) Immunostaining for von Willebrand factor (VWF) and smooth muscle actin (SMA) in control, placebo-treated, and cardiosphere-derived
cell (CDC)–treated rats. CDC treatment increases arteriolar (B) and capillary (C) density in the left ventricle. (D) Immunostaining for Ki67 and
a-actinin (SA) and for Ki67 and vimentin in control, placebo-treated, and CDC-treated rats. CDC treatment increased cardiomyocyte (CM)
proliferation (E) and decreased the proliferation of ﬁbroblasts (F) compared with placebo. n ¼ 5 in each group. †p < 0.05 versus control and
CDC-treated rats, both by analysis of variance; ‡p < 0.05 versus control and placebo-treated rats. DAPI ¼ 40,6-diamidino-2-phenylindole.
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FIGURE 8 Transcriptomic Analysis Reveals Profound CDC-Responsive Changes of Gene Expression in HFpEF
(A) Heat map showing the transcripts that are up- or downregulated by heart failure with preserved ejection fraction (HFpEF) and
normalized partially or completely by cardiosphere-derived cell (CDC) treatment. (B) Selected genes involved in inﬂammation
and ﬁbrosis or associated with HFpEF that are rescued by CDC treatment (abbreviations in Supplemental Table 1). (C) Selected
pathways modiﬁed by CDC treatment compared with placebo; blue, inhibited; orange, activated; white, not clear from the database
(published research missing).
Gallet et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 1 - 2 , 2 0 1 6
Cell Therapy With CDCs in HFpEF J A N U A R Y / F E B R U A R Y 2 0 1 6 : 1 4 – 2 8
243 groups. Supplemental Figures 2A to 2C show head-
to-head pairwise comparison of gene expression in
the 3 groups. The heat maps reveal that the HFpEF
phenotype is associated with major global changes
in gene expression, as shown by the comparison
between placebo and control groups (Supplemental
Figure 2A). More important, the comparison be-
tween CDC- and placebo-treated rats (Supplemental
Figure 2B) reveals that CDC treatment dramatically
changed gene expression. Interestingly, >300 genes
whose expression was up- or downregulated in
HFpEF (i.e., in high-salt placebo hearts) had their
expression levels “rescued” by CDC treatment
(Figure 8A). Some of these transcript changes
involved genes that underlie HFpEF-related patho-
physiologic features that we and others haveidentiﬁed (a nonexhaustive list is shown in
Figure 8B). Indeed, key genes involved in ﬁbrosis,
inﬂammation, and macrophage signaling, or associ-
ated with the consequences of HFpEF (brain natri-
uretic and atrial natriuretic peptides), were
upregulated in placebo hearts but returned fully
or partially to control levels after CDC treatment.
These profound changes in the transcriptome reveal
HFpEF-related activation, and CDC-induced inhibi-
tion, of key disease-associated signaling and effector
pathways (Figure 8C).
DISCUSSION
The challenge of HFpEF is increasing as the popu-
lation ages and comorbidities become more
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25prevalent. The HFpEF hospitalization rate is now
greater than that for heart failure with reduced
LVEF (3). So far, no treatment for HFpEF has proved
effective (6). Here, we have demonstrated that cell
therapy by CDCs can reverse the functional abnor-
malities of HFpEF and improve survival in a rat
model of hypertension-induced HFpEF. The CDC-
induced reversal of HFpEF occurred without a
reduction in either blood pressure or cardiac
hypertrophy. The selective correction of functional
HFpEF abnormalities creates an unprecedented
opportunity for mechanistic insights. Potentially
causal pathways (i.e., those that accompany the
abnormalities in HFpEF) can now be distinguished
from those that are merely associative. Our ﬁndings
support the concept that ﬁbrosis and inﬂammation
are causative in HFpEF (10): reductions in those 2
pathophysiological processes underlie the resolution
of HFpEF, while hypertrophy and hypertension
remain unchanged.
Cardiac hypertrophy has long been thought to be
the linchpin in HFpEF (8,41,42). However, several
recent studies in animal models and humans have
implicated inﬂammation and collagen inﬁltration
(10,12–14,43–45). Hypertension and other comor-
bidities can favor a systemic proinﬂammatory state
with high circulating cytokine levels, including
interleukin-6, tumor necrosis factor–a, and mono-
cyte chemotactic protein–1 (9,10,37). Inﬂammation
leads to activation, recruitment, and trans-
endothelial migration of leukocytes and monocytes
or macrophages into the heart. These inﬂammatory
cells contribute to LV ﬁbrosis by promoting the
differentiation of ﬁbroblasts into myoﬁbroblasts
(33,46,47). The resulting increase in LV collagen
content is the main contributor to the increase in
passive myocardial ﬁber stiffness, a major compo-
nent of diastolic impairment in HFpEF (12). The
observed phenotypic improvements after CDC
treatment were associated with decreases in cir-
culating inﬂammatory cytokines (including
interleukin-6, tumor necrosis factor–a, and mono-
cyte chemotactic protein-1) and less myocardial
inﬂammation. In addition, myoﬁbroblast inﬁltra-
tion, collagen content, and collagen production
were increased in placebo-treated animals but fell
markedly after CDC treatment. The parallel
decrease in transcripts for MMPs and TIMPs
(Supplemental Figure 1) suggests, but does not
prove, increased extracellular matrix turnover in
the placebo-treated animals that is normalized by
CDC treatment. Increased extracellular matrix
turnover in HFpEF has been described, and MMPsand TIMPs have been suggested as biomarkers for
the diagnosis and prognosis of HFpEF (48–50).
Taken together, these ﬁndings strengthen the hy-
pothesis that proinﬂammatory and proﬁbrotic
stimuli play a major role in the development of
HFpEF (10). Furthermore, our results suggest that
modulating those stimuli may improve HFpEF
phenotype and outcomes. The mechanism whereby
CDCs modify inﬂammation and ﬁbrosis clearly in-
volves major changes in gene expression
(Figure 8C). Such changes are long-lasting, as the
transcriptome was analyzed 4 weeks after CDC in-
jection (at which point injected allogeneic cells are
no longer detectable) (18). Our working hypothesis
posits that CDCs secrete exosomes laden with
micro-ribonucleic acids and other noncoding ribo-
nucleic acids that collectively mold the target
transcriptome. Although in-depth exploration of
this hypothesis is beyond the scope of this initial
report, multiple lines of evidence in other models
show that exosomes mediate the beneﬁts of CDCs
and modify phenotype and gene expression in recip-
ient cells (51–53). We are intrigued by the possibility
that the drastic changes in the expression of the
genes involved in ﬁbrosis and inﬂammation seen here
may be in vivo manifestations of exosome-mediated
phenotypic conversions such as those we have
described in skin ﬁbroblasts (52).
It is noteworthy that no changes in the magni-
tude of cardiac hypertrophy were observed after
CDC treatment. Cardiac hypertrophy assessed using
3 different techniques (echocardiography, heart
weight, and cardiomyocyte cross-sectional area) was
present and virtually identical in both high-salt
groups at endpoint but not in control rats. Here,
decreased inﬂammation and ﬁbrosis underlie the
resolution of HFpEF, despite persistent hypertrophy
and hypertension. Thus, attenuation of cardiac hy-
pertrophy is not required to normalize diastolic
function. Regarding the mechanical properties of
the cardiomyocytes, we observed that CDCs
enhance cardiomyocyte (but not ﬁbroblast) prolif-
eration. Nevertheless, the absolute number of new
myocytes remains low, and cardiomyocytes remain
hypertrophic after CDC treatment. Thus, the
correction of altered mechanical properties is more
likely related to intrinsic changes in preexisting
cardiomyocytes than to a dominant effect of newly
generated cardiomyocytes. Our ongoing character-
ization of cardiomyocytes isolated from the various
groups is consistent with this prediction, but
such studies are beyond the scope of this initial
report.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Intracoronary CDC administration normalizes diastolic
function and improves survival in rats with HFpEF.
Reversal of inﬂammation and ﬁbrosis, but not atten-
uation of cardiac hypertrophy, underlies these func-
tional beneﬁts.
TRANSLATIONAL OUTLOOK: Given that CDCs are
already in advanced clinical testing for other indi-
cations, the present study motivates clinical trials of
CDCs in HFpEF. Also, the selective correction of
functional HFpEF abnormalities observed here
creates an unprecedented opportunity for mecha-
nistic insights.
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26Microvascular dysfunction and rarefaction have
been reported as additional contributors to HFpEF.
Several studies have shown that even in the absence
of coronary artery disease, patients with HFpEF
have fewer microvessels and lower coronary reserve
(38–40). In addition to their anti-inﬂammatory and
antiﬁbrotic properties, CDCs are able to promote the
growth of new vessels (18,21). We observed increases
in the numbers of arterioles and capillaries in the
left ventricle after CDC treatment (Figure 7). Although
the vascular ﬁndings here are limited to histologic
ﬁndings, we have previously demonstrated that
cardiosphere-related increases in vessels by histology
were associated with augmented myocardial perfu-
sion and coronary reserve (54).
STUDY LIMITATIONS. HFpEF is a multifactorial dis-
ease involving aging and cardiovascular risk factors.
Although DS rats reproduce most of the key features
of HFpEF (including hypertension, inﬂammation,
ﬁbrosis, and microvascular rarefaction), some typical
contributors to this disease (especially aging) are ab-
sent in this model. Also, our follow-up was relatively
short. Because death and/or progression toward sys-
tolic dysfunction occurs in DS rats around 19 to 20
weeks of age (55,56), we decided to set the endpoint
before the terminal decrease in LVEF, which might
otherwise have confounded the analysis of HFpEF.
Therefore, we have no information (other than the
observed mortality beneﬁt at 6 weeks) regarding the
potential long-term persistence of the beneﬁt.
Regarding remodeling of the extracellular matrix, we
have shown directionally appropriate changes in
various transcripts and proteins, but we have not
performed zymography to directly evaluate MMP
activity. Finally, we have yet to demonstrate the
involvement of exosomes and micro-ribonucleicacids in the dramatic changes observed after CDC
treatment here. For now, the proposed mechanisms
remain at the level of plausibility, as bolstered by
previous studies (51,52).
CONCLUSIONS
CDCs normalized LV relaxation and improved sur-
vival in a rat model of HFpEF, without blunting
hypertension or hypertrophy. Given that CDCs are
already in advanced clinical testing for other in-
dications (57), the present ﬁndings motivate clinical
trials of CDCs in HFpEF.
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